ncRNA basic information ncRNA ID: MI0000077 ncRNA Database: miRBase ncRNA Name: miR-21 ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-PCR ncRNA Target Gene: PDCD4 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB01169 (APRD00171) Drug Name: Arsenic trioxide Drug Method: In the study, we used a specific precursor miRNA-21 (pre-miR-21) or anti-miRNA-21 oligonucleotide (AMO-miR-21) to study sensitivity of HL60 and K562 cells to ATO. Cell viability and cell cycle were evaluated by MTT assay and PI assay using flow cytometry, respectively. Levels of miR-21 and its target PDCD4 were quantified by real-time PCR and/or western blot. AMO-miR-21 or ATO alone led to growth inhibition, apoptosis and G1 phase arrest of cell cycle. Apoptotic cells were confirmed morphologically with Hoechst staining. Moreover, there was somewhat synergistic effect of AMO-miR-21 and ATO in growth inhibition and apoptosis promotion. Meanwhile, enforced pre-miR-21 expression increased resistance to ATO, nevertheless not affecting cell growth alone. Dual-luciferase reporter vector containing two tandem PDCD4 3 UTR validated that PDCD4 was directly up-regulated by miR-21. Therefore, miRNA-21 by targeting PDCD4 may play a functional role in modulating ATO-induced cell death, and strategy using AMO-miR-21 and its combination with ATO may be useful as a myelogenous leukemia therapy. Drug Response: resistant

Cancer basic information Cancer: leukemia Tissue/Cell: cell line ( HL60, K562)

Other information Title: miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Journal: Med Oncol Published: 2011 PubMed ID: 20143188